TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 84 filers reported holding TCR2 THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $31,749 | -61.9% | 21,166 | -74.7% | 0.00% | – |
Q4 2022 | $83,371 | -60.9% | 83,538 | -29.6% | 0.00% | – |
Q3 2022 | $213,000 | -46.8% | 118,667 | -14.0% | 0.00% | – |
Q2 2022 | $400,000 | -32.9% | 137,944 | -36.1% | 0.00% | – |
Q1 2022 | $596,000 | -89.6% | 215,926 | -82.4% | 0.00% | -100.0% |
Q4 2021 | $5,728,000 | +593.5% | 1,229,279 | +1166.3% | 0.00% | – |
Q3 2021 | $826,000 | +419.5% | 97,073 | +901.4% | 0.00% | – |
Q2 2021 | $159,000 | -56.4% | 9,694 | -41.3% | 0.00% | – |
Q1 2021 | $365,000 | +91.1% | 16,505 | +167.3% | 0.00% | – |
Q4 2020 | $191,000 | +60.5% | 6,175 | +5.2% | 0.00% | – |
Q3 2020 | $119,000 | +7.2% | 5,871 | -19.1% | 0.00% | – |
Q2 2020 | $111,000 | +311.1% | 7,253 | +108.4% | 0.00% | – |
Q1 2020 | $27,000 | -73.0% | 3,480 | -50.2% | 0.00% | – |
Q4 2019 | $100,000 | +51.5% | 6,990 | +57.4% | 0.00% | – |
Q3 2019 | $66,000 | +10.0% | 4,440 | +5.7% | 0.00% | – |
Q2 2019 | $60,000 | +46.3% | 4,202 | +78.6% | 0.00% | – |
Q1 2019 | $41,000 | – | 2,353 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
MPM BioImpact LLC | 6,741,964 | $208,528,000 | 18.01% |
MPM ASSET MANAGEMENT LLC | 4,050,865 | $125,293,000 | 17.73% |
Consonance Capital Management LP | 584,885 | $71,268,000 | 6.66% |
SILVERARC CAPITAL MANAGEMENT, LLC | 136,000 | $4,206,000 | 2.44% |
Redmile Group, LLC | 2,832,888 | $87,621,000 | 1.06% |
Altium Capital Management LP | 73,991 | $2,289,000 | 0.86% |
PFM Health Sciences, LP | 775,794 | $23,995,000 | 0.84% |
Soleus Capital Management, L.P. | 199,867 | $6,182,000 | 0.82% |
MOODY ALDRICH PARTNERS LLC | 123,639 | $3,824,000 | 0.62% |
Sofinnova Investments, Inc. | 333,707 | $10,322,000 | 0.61% |